Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Payables (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Payables for 5 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 12.6% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 12.6% year-over-year, with the annual reading at $4.6 million for FY2025, 12.6% up from the prior year.
  • Payables hit $4.6 million in Q4 2025 for ARS Pharmaceuticals, down from $49.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $49.8 million in Q3 2025 to a low of $126000.0 in Q3 2022.
  • Historically, Payables has averaged $10.7 million across 5 years, with a median of $4.8 million in 2022.
  • Biggest five-year swings in Payables: tumbled 92.67% in 2022 and later surged 8586.51% in 2023.
  • Year by year, Payables stood at $6.6 million in 2021, then decreased by 25.13% to $4.9 million in 2022, then tumbled by 56.32% to $2.2 million in 2023, then skyrocketed by 88.72% to $4.1 million in 2024, then rose by 12.6% to $4.6 million in 2025.
  • Business Quant data shows Payables for SPRY at $4.6 million in Q4 2025, $49.8 million in Q3 2025, and $44.3 million in Q2 2025.